Clinical Trials Insights
Drug Discovery & Development
Renaissance Pharma secures FDA Fast Track Designation and IND clearance for Daretabart in high-risk neuroblastoma
The US Food and Drug Administration (FDA) has granted Fast Track Designation for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody in development for the...
Clinical Trials Insights
AbbVie’s Elahere succeeds in phase 2 platinum-sensitive ovarian cancer trial
AbbVie has announced that late-breaking results from the phase 2 IMGN853-0420 trial.
The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug...
Drug Discovery & Development
Oragenics doses first patient in phase 2a clinical trial of drug for mild traumatic brain injury
Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, has announced that the first patient has been dosed in its...
Drug Discovery & Development
Lynk Pharmaceuticals announces NDA acceptance for zemprocitinib
Lynk Pharmaceuticals, a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, has announced that the New Drug Application (NDA)...
Clinical Trials Insights
MetaVia doses the first patient in higher-dose phase 1 study of DA-1726, Its GLP-1 and glucagon dual agonist for the treatment of obesity
MetaVia, a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, has announced that the first patient has been dosed in part 3 of its...
Clinical Trials Insights
Ideaya Biosciences and Servier announce positive topline results from phase 2/3 registrational trial of darovasertib in combination with crizotinib in first-line negative metastatic uveal...
IDEAYA Biosciences, a precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, have announced positive topline results from...
Clinical Trials Insights
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers
GSK has announced positive findings from its global phase 1 BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate...
Clinical Trials Insights
UCB announces new clinical data from its generalised myasthenia gravis (gMG) portfolio
UCB, a global biopharmaceutical company, has announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well...
- Advertisement -
- Advertisement -
Latest stories
© 2026 Pharma Press Publishing.